SG11201807062RA - Anti-tnfalpha-antibodies and functional fragments thereof - Google Patents
Anti-tnfalpha-antibodies and functional fragments thereofInfo
- Publication number
- SG11201807062RA SG11201807062RA SG11201807062RA SG11201807062RA SG11201807062RA SG 11201807062R A SG11201807062R A SG 11201807062RA SG 11201807062R A SG11201807062R A SG 11201807062RA SG 11201807062R A SG11201807062R A SG 11201807062RA SG 11201807062R A SG11201807062R A SG 11201807062RA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- pct
- functional fragments
- rheinfelden
- english
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/241—Tumor Necrosis Factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/626—Diabody or triabody
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property -, Organization 1111411011101010111110101111 101E3 1011110110111010111111101111011# International Bureau .. .... ..Yejd (10) International Publication Number (43) International Publication Date .... ...,,, WO 2017/158092 Al 21 September 2017 (21.09.2017) WIP0 I PCT (51) International Patent Classification: C07K 16/24 (2006.01) AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, (21) International Application Number: PCT/EP2017/056237 HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, (22) International Filing Date: 16 March 2017 (16.03.2017) MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, (25) Filing Language: English TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, (26) Publication Language: English ZA, ZM, ZW. (30) Priority Data: (84) Designated States (unless otherwise indicated, for every 16160907.8 17 March 2016 (17.03.2016) EP kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, (71) Applicant: TILLOTTS PHARMA AG [CH/CH]; Basler- strasse 15, 4310 Rheinfelden (CH). TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, (72) Inventors: GUNDE, Tea; Turbinenstrasse 33, 8005 Zuerich (CH). MEYER, Sebastian; Kirchrainstrasse 6, 5445 Eggenwil (CH). FURRER, Esther Maria; c/o Tillotts Pharma AG, Baslerstrasse 15, 4310 Rheinfelden DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, L V, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). (CH). Published: Agents: KALHAMMER, Georg et al.; Unsoldstr. 2, (74) — with international search report (Art. 21(3)) 80538 Miinchen (DE). — with sequence listing part of description (Rule 5.2(a)) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, (81) = 1-1 ei tz. © cc ir) 11 IN 11 0 \" (54) Title: ANTI-TNFALPHA-ANTIBODIES AND FUNCTIONAL FRAGMENTS THEREOF C: ) ,.. (57) : The present invention relates to antibody molecules and functional fragments thereof, capable of binding to tumor necrosis factor alpha (TNFa), to processes for their production, and to their therapeutic uses.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP16160907.8A EP3219726B1 (en) | 2016-03-17 | 2016-03-17 | Anti-tnf alpha-antibodies and functional fragments thereof |
PCT/EP2017/056237 WO2017158092A1 (en) | 2016-03-17 | 2017-03-16 | Anti-tnfalpha-antibodies and functional fragments thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201807062RA true SG11201807062RA (en) | 2018-09-27 |
Family
ID=55542576
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201807062RA SG11201807062RA (en) | 2016-03-17 | 2017-03-16 | Anti-tnfalpha-antibodies and functional fragments thereof |
Country Status (39)
Country | Link |
---|---|
US (3) | US11459383B2 (en) |
EP (3) | EP3219726B1 (en) |
JP (2) | JP7129398B2 (en) |
KR (2) | KR20220158877A (en) |
CN (1) | CN109071650B (en) |
AR (1) | AR107917A1 (en) |
AU (1) | AU2017235387B2 (en) |
BR (1) | BR112018016667A2 (en) |
CA (1) | CA3011784C (en) |
CL (1) | CL2018002649A1 (en) |
CO (1) | CO2018009783A2 (en) |
CR (1) | CR20180448A (en) |
CY (1) | CY1123784T1 (en) |
DK (2) | DK3219726T3 (en) |
EA (1) | EA039760B1 (en) |
ES (2) | ES2836349T3 (en) |
FI (1) | FI3430043T3 (en) |
GE (1) | GEP20217307B (en) |
HR (2) | HRP20231464T1 (en) |
HU (2) | HUE052773T2 (en) |
IL (1) | IL261031A (en) |
JO (2) | JOP20170064B1 (en) |
LT (2) | LT3219726T (en) |
MA (1) | MA43717B1 (en) |
MD (1) | MD3430043T2 (en) |
MX (1) | MX2018011258A (en) |
MY (1) | MY194041A (en) |
PH (1) | PH12018501907A1 (en) |
PL (2) | PL3219726T3 (en) |
PT (2) | PT3219726T (en) |
RS (2) | RS61374B1 (en) |
SA (1) | SA518400027B1 (en) |
SG (1) | SG11201807062RA (en) |
SI (2) | SI3219726T1 (en) |
TN (1) | TN2018000298A1 (en) |
TW (2) | TWI784945B (en) |
UY (1) | UY37157A (en) |
WO (1) | WO2017158092A1 (en) |
ZA (4) | ZA202108601B (en) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BR112018017276A2 (en) | 2016-03-17 | 2019-02-05 | Numab Innovation Ag | anti-tnf-alpha antibodies and functional fragments thereof |
EP3219727B1 (en) | 2016-03-17 | 2020-12-16 | Tillotts Pharma AG | Anti-tnf alpha-antibodies and functional fragments thereof |
CA3011502A1 (en) | 2016-03-17 | 2017-09-21 | Numab Innovation Ag | Anti-tnf.alpha.-antibodies and functional fragments thereof |
PL3219726T3 (en) * | 2016-03-17 | 2021-07-19 | Tillotts Pharma Ag | Anti-tnf alpha-antibodies and functional fragments thereof |
PT3456736T (en) * | 2017-09-19 | 2021-05-28 | Tillotts Pharma Ag | Antibody variants |
ES2978167T3 (en) * | 2017-09-19 | 2024-09-06 | Tillotts Pharma Ag | Antibody variants |
EP3456738B1 (en) * | 2017-09-19 | 2024-07-17 | Tillotts Pharma Ag | Antibody variants |
WO2020114616A1 (en) | 2018-12-07 | 2020-06-11 | Tillotts Pharma Ag | Topical treatment of immune checkpoint inhibitor induced diarrhoea, colitis or enterocolitis using antibodies and fragments thereof |
Family Cites Families (54)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4444887A (en) | 1979-12-10 | 1984-04-24 | Sloan-Kettering Institute | Process for making human antibody producing B-lymphocytes |
US4716111A (en) | 1982-08-11 | 1987-12-29 | Trustees Of Boston University | Process for producing human antibodies |
GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US5807715A (en) | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
GB8720833D0 (en) | 1987-09-04 | 1987-10-14 | Celltech Ltd | Recombinant dna product |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
GB8907617D0 (en) | 1989-04-05 | 1989-05-17 | Celltech Ltd | Drug delivery system |
US5413923A (en) | 1989-07-25 | 1995-05-09 | Cell Genesys, Inc. | Homologous recombination for universal donor cells and chimeric mammalian hosts |
GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
DE69133566T2 (en) | 1990-01-12 | 2007-12-06 | Amgen Fremont Inc. | Formation of xenogenic antibodies |
GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
EP0814159B1 (en) | 1990-08-29 | 2005-07-27 | GenPharm International, Inc. | Transgenic mice capable of producing heterologous antibodies |
US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
GB9109645D0 (en) | 1991-05-03 | 1991-06-26 | Celltech Ltd | Recombinant antibodies |
US5919452A (en) | 1991-03-18 | 1999-07-06 | New York University | Methods of treating TNFα-mediated disease using chimeric anti-TNF antibodies |
DE69233482T2 (en) | 1991-05-17 | 2006-01-12 | Merck & Co., Inc. | Method for reducing the immunogenicity of antibody variable domains |
IE922437A1 (en) | 1991-07-25 | 1993-01-27 | Idec Pharma Corp | Recombinant antibodies for human therapy |
ES2136092T3 (en) | 1991-09-23 | 1999-11-16 | Medical Res Council | PROCEDURES FOR THE PRODUCTION OF HUMANIZED ANTIBODIES. |
ATE408012T1 (en) | 1991-12-02 | 2008-09-15 | Medical Res Council | PRODUCTION OF AUTOANTIBODIES ON PHAGE SURFACES BASED ON ANTIBODIES SEGMENT LIBRARIES |
US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
NO309690B1 (en) | 1995-01-23 | 2001-03-12 | Western Atlas Int Inc | Detonator type exploding wire for use with a perforation tool in a well |
ATE390933T1 (en) | 1995-04-27 | 2008-04-15 | Amgen Fremont Inc | HUMAN ANTIBODIES AGAINST IL-8 DERIVED FROM IMMUNIZED XENOMICES |
AU2466895A (en) | 1995-04-28 | 1996-11-18 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
BRPI9715219B8 (en) * | 1996-02-09 | 2015-07-07 | Abbvie Biotechnology Ltd | Recombinant expression vector, and prokaryotic host cell. |
US5916771A (en) | 1996-10-11 | 1999-06-29 | Abgenix, Inc. | Production of a multimeric protein by cell fusion method |
AU5702298A (en) | 1996-12-03 | 1998-06-29 | Abgenix, Inc. | Transgenic mammals having human Ig loci including plural VH and VK regions nd antibodies produced therefrom |
GB9625640D0 (en) | 1996-12-10 | 1997-01-29 | Celltech Therapeutics Ltd | Biological products |
SI0970126T1 (en) | 1997-04-14 | 2001-08-31 | Micromet Ag | Novel method for the production of antihuman antigen receptors and uses thereof |
US6235883B1 (en) | 1997-05-05 | 2001-05-22 | Abgenix, Inc. | Human monoclonal antibodies to epidermal growth factor receptor |
EP1135498B1 (en) | 1998-11-18 | 2008-01-23 | Genentech, Inc. | Antibody variants with higher binding affinity compared to parent antibodies |
GB0412181D0 (en) | 2004-06-01 | 2004-06-30 | Celltech R&D Ltd | Biological products |
US7431927B2 (en) | 2005-03-24 | 2008-10-07 | Epitomics, Inc. | TNFα-neutralizing antibodies |
BRPI0611765B1 (en) | 2005-06-07 | 2022-09-27 | Esbatech Ag | STABLE AND SOLUBLE ANTIBODY OR FRAGMENT THAT SPECIFICALLY BINDS TO TNF-ALFA ITS USES AND DIAGNOSTIC OR THERAPEUTIC COMPOSITION |
JP5856480B2 (en) | 2008-06-25 | 2016-02-09 | エスバテック − ア ノバルティスカンパニー エルエルシー | Humanization of rabbit antibodies using a versatile antibody framework |
ES2861592T3 (en) | 2008-06-25 | 2021-10-06 | Novartis Ag | Stable and soluble antibodies that inhibit TNF |
BRPI0915460A2 (en) | 2008-07-10 | 2015-11-10 | Esbatech Alcon Biomed Res Unit | methods and compositions for enhanced release of macromolecules |
RU2012147249A (en) * | 2010-04-07 | 2014-05-20 | Эббви Инк. | TNF-α- BINDING PROTEINS |
CN108314733A (en) * | 2010-07-16 | 2018-07-24 | 埃博灵克斯股份有限公司 | The single domain antigen binding molecules of modification and its application |
US9096669B2 (en) * | 2010-09-30 | 2015-08-04 | Chengdu Kanghong Biotechnologies Co., Ltd. | Humanized anti-TNF-α antibody and antigen-binding fragment (Fab) thereof and use of the same |
KR102286053B1 (en) | 2013-06-26 | 2021-08-04 | 누맙 세러퓨틱스 아게 | Novel Antibody Frameworks |
CA2924520C (en) * | 2013-11-01 | 2023-09-26 | Ibc Pharmaceuticals, Inc. | Bispecific antibodies that neutralize both tnf-alpha and il-6: novel therapeutic agent for autoimmune disease |
BR112016022055A2 (en) * | 2014-03-26 | 2017-10-24 | Cell Medica Switzerland Ag | alpha tnf binding elements |
EP3219727B1 (en) | 2016-03-17 | 2020-12-16 | Tillotts Pharma AG | Anti-tnf alpha-antibodies and functional fragments thereof |
BR112018017276A2 (en) | 2016-03-17 | 2019-02-05 | Numab Innovation Ag | anti-tnf-alpha antibodies and functional fragments thereof |
PL3219726T3 (en) * | 2016-03-17 | 2021-07-19 | Tillotts Pharma Ag | Anti-tnf alpha-antibodies and functional fragments thereof |
CA3011502A1 (en) | 2016-03-17 | 2017-09-21 | Numab Innovation Ag | Anti-tnf.alpha.-antibodies and functional fragments thereof |
-
2016
- 2016-03-17 PL PL16160907T patent/PL3219726T3/en unknown
- 2016-03-17 RS RS20210112A patent/RS61374B1/en unknown
- 2016-03-17 PT PT161609078T patent/PT3219726T/en unknown
- 2016-03-17 DK DK16160907.8T patent/DK3219726T3/en active
- 2016-03-17 HU HUE16160907A patent/HUE052773T2/en unknown
- 2016-03-17 LT LTEP16160907.8T patent/LT3219726T/en unknown
- 2016-03-17 SI SI201631040T patent/SI3219726T1/en unknown
- 2016-03-17 EP EP16160907.8A patent/EP3219726B1/en active Active
- 2016-03-17 ES ES16160907T patent/ES2836349T3/en active Active
-
2017
- 2017-03-16 FI FIEP17710748.9T patent/FI3430043T3/en active
- 2017-03-16 CA CA3011784A patent/CA3011784C/en active Active
- 2017-03-16 HU HUE17710748A patent/HUE064238T2/en unknown
- 2017-03-16 JP JP2019500013A patent/JP7129398B2/en active Active
- 2017-03-16 AU AU2017235387A patent/AU2017235387B2/en active Active
- 2017-03-16 WO PCT/EP2017/056237 patent/WO2017158092A1/en active Application Filing
- 2017-03-16 MY MYPI2018001566A patent/MY194041A/en unknown
- 2017-03-16 LT LTEPPCT/EP2017/056237T patent/LT3430043T/en unknown
- 2017-03-16 EP EP23192170.1A patent/EP4275745A3/en active Pending
- 2017-03-16 MA MA43717A patent/MA43717B1/en unknown
- 2017-03-16 EP EP17710748.9A patent/EP3430043B1/en active Active
- 2017-03-16 US US16/085,506 patent/US11459383B2/en active Active
- 2017-03-16 GE GEAP201714876A patent/GEP20217307B/en unknown
- 2017-03-16 KR KR1020227040533A patent/KR20220158877A/en not_active Application Discontinuation
- 2017-03-16 ES ES17710748T patent/ES2963221T3/en active Active
- 2017-03-16 DK DK17710748.9T patent/DK3430043T3/en active
- 2017-03-16 EA EA201891788A patent/EA039760B1/en unknown
- 2017-03-16 MD MDE20190099T patent/MD3430043T2/en unknown
- 2017-03-16 PT PT177107489T patent/PT3430043T/en unknown
- 2017-03-16 BR BR112018016667A patent/BR112018016667A2/en unknown
- 2017-03-16 SG SG11201807062RA patent/SG11201807062RA/en unknown
- 2017-03-16 KR KR1020187022632A patent/KR102470235B1/en active IP Right Grant
- 2017-03-16 CN CN201780015298.5A patent/CN109071650B/en active Active
- 2017-03-16 CR CR20180448A patent/CR20180448A/en unknown
- 2017-03-16 MX MX2018011258A patent/MX2018011258A/en unknown
- 2017-03-16 RS RS20231087A patent/RS64830B1/en unknown
- 2017-03-16 PL PL17710748.9T patent/PL3430043T3/en unknown
- 2017-03-16 SI SI201731446T patent/SI3430043T1/en unknown
- 2017-03-16 HR HRP20231464TT patent/HRP20231464T1/en unknown
- 2017-03-16 TN TNP/2018/000298A patent/TN2018000298A1/en unknown
- 2017-03-16 JO JOP/2017/0064A patent/JOP20170064B1/en active
- 2017-03-17 TW TW106108832A patent/TWI784945B/en active
- 2017-03-17 UY UY0001037157A patent/UY37157A/en not_active Application Discontinuation
- 2017-03-17 AR ARP170100675A patent/AR107917A1/en unknown
- 2017-03-17 TW TW111145252A patent/TWI829444B/en active
-
2018
- 2018-08-07 IL IL261031A patent/IL261031A/en unknown
- 2018-09-06 PH PH12018501907A patent/PH12018501907A1/en unknown
- 2018-09-14 CL CL2018002649A patent/CL2018002649A1/en unknown
- 2018-09-16 SA SA518400027A patent/SA518400027B1/en unknown
- 2018-09-17 CO CONC2018/0009783A patent/CO2018009783A2/en unknown
-
2021
- 2021-01-13 CY CY20211100021T patent/CY1123784T1/en unknown
- 2021-01-22 HR HRP20210123TT patent/HRP20210123T1/en unknown
- 2021-04-22 JO JOP/2021/0085A patent/JOP20210085A1/en unknown
- 2021-11-04 ZA ZA2021/08601A patent/ZA202108601B/en unknown
- 2021-11-04 ZA ZA2021/08600A patent/ZA202108600B/en unknown
- 2021-11-04 ZA ZA2021/08602A patent/ZA202108602B/en unknown
- 2021-11-04 ZA ZA2021/08599A patent/ZA202108599B/en unknown
-
2022
- 2022-06-06 JP JP2022091271A patent/JP2022130407A/en active Pending
- 2022-08-18 US US17/890,857 patent/US12043663B2/en active Active
- 2022-10-03 US US17/958,759 patent/US20230279091A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11201807062RA (en) | Anti-tnfalpha-antibodies and functional fragments thereof | |
SG11201903857UA (en) | Antibodies to pd-1 and uses thereof | |
SG11201908391XA (en) | Methods for modulating an immune response | |
SG11201909949XA (en) | Targeted immunotolerance | |
SG11201810003UA (en) | Using programmable dna binding proteins to enhance targeted genome modification | |
SG11201901126UA (en) | Combination therapy for cancer | |
SG11201809064QA (en) | Chimeric neurotoxins | |
SG11201807401RA (en) | Therapeutic membrane vesicles | |
SG11201811432WA (en) | Rna for cancer therapy | |
SG11201901307VA (en) | Heterodimeric immunoglobulin constructs and preparation methods thereof | |
SG11201807252QA (en) | Anti-lag-3 antibodies | |
SG11201901494UA (en) | Acid-alpha glucosidase variants and uses thereof | |
SG11201811290VA (en) | Compositions and methods for the depletion of cd117+cells | |
SG11201804510PA (en) | Biparatopic polypeptides antagonizing wnt signaling in tumor cells | |
SG11201810423XA (en) | Pd-1 / pd-l1 inhibitors for cancer treatment | |
SG11201811048UA (en) | Single-cell transcript sequencing | |
SG11201808125RA (en) | Methods for solid tumor treatment | |
SG11201900746RA (en) | Engineered antibodies and other fc-domain containing molecules with enhanced agonism and effector functions | |
SG11201807827VA (en) | Process for the preparation of pegylated drug-linkers and intermediates thereof | |
SG11201805001UA (en) | Method of treating influenza a | |
SG11201903076QA (en) | Carbamoyl phenylalaninol compounds and uses therof | |
SG11201809374VA (en) | Cd40l-fc fusion polypeptides and methods of use thereof | |
SG11201900361RA (en) | Methods of treating prostate cancer | |
SG11201907927SA (en) | Binding molecules that specifically bind to tau | |
SG11201809594WA (en) | Nicotine particles and compositions |